( September 2, 2026, 8:08 AM EDT) -- WASHINGTON, D.C. — Substantial evidence supported the U.S. Patent Trial and Appeal Board’s (PTAB) factual findings that led to it determining that all claims in multiple patents held by a genomics company were unpatentable as obvious, a Federal Circuit U.S. Court of Appeals panel held; the panel rejected the appellant company’s challenge to PTAB’s motivation-to-combine analysis and other elements of its findings....